ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

AI Summary

Ai3Bio, formed from two biotechnology companies, is developing an approach to autoimmune disease that differs from therapies targeting B cells. Its treatments are designed to eliminate a specific group of T helper cells as a potential route to an immune reset.

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.